5 Key Takeaways

• 1

  Biosimilars show comparable outcomes to originator drugs in treating noninfectious uveitis, but further research is necessary.

• 2

  First-line therapy for noninfectious uveitis often includes steroids, with immunosuppression used for long-term control.

• 3

  In pediatric patients, biosimilars significantly reduced ocular uveitis recurrences and enabled glucocorticoid-sparing effects.

• 4

  Adult patients switching to biosimilars experienced reduced uveitis relapse rates and improved visual acuity.

• 5

  Current literature indicates similar efficacy between biosimilars and originator drugs, but some patients may experience increased flare rates after switching.